Abstract. It has been hypothesized that dysregulated host/microbial interactions play a pivotal role in the pathogenesis of inflammatory bowel disease. However, the exact mechanisms underlying the induction and perpetuation of the intestinal disorder are unclear. Recently, we unexpectedly discovered significantly upregulated gene expression of chitinase 3-like-1 in inflamed colon of the dextran sulfate sodium-induced colitis model by employing the DNA-microarray analysis. Chitinase 3-like-1 has a chitin binding ability, but lacks the enzymatic activity of lysing microbial cell wall. Chitinase 3-like-1 protein is mainly expressed in colonic epithelial cells and macrophages in the inflamed colon of dextran sulfate sodium-induced colitis. Chitinase 3-like-1, which can be upregulated after pro-inflammatory cytokine stimulation, possesses an ability to enhance the adhesion and internalization of intracellular bacteria into colonic epithelial cells. Most importantly, in vivo neutralization of chitinase 3-like-1 significantly suppressed the development of dextran sulfate sodiuminduced colitis by dramatically decreasing the bacterial adhesion and invasion into colonic epithelial cells. Furthermore, anti-chitinase 3-like-1 antibody-treated mice exhibited a significantly lower load of Salmonella typhimurium in peripheral organs as compared to control rabbit IgG-treated mice. Recently, it has been reported that acidic mammalian chitinase is expressed in the setting of T helper-2-associated inflammation and subsequently induces airway hyperresponsiveness in allergic asthma patients. In addition, pan-chitinase inhibitor significantly ameliorates T helper-2-mediated inflammation and airway hypersensitivity. These studies provide to be a novel insight into the physiological role of mammalian chitinases in host/microbial interactions, and inhibition of chitinase activity would be considered a novel therapeutic strategy of allergic and inflammatory disorders. (Keio J Med 56 (1) : 21 -27,
Introduction
Inflammatory bowel disease (IBD), consisting of Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing and remitting, inflammatory condition that affects individuals throughout their lives. 1 Although the pathogenesis of IBD is still unknown, it has been widely accepted that genetic and environmental factors and immunological abnormalities are involved in this pathogenesis. Recent clinical and experimental studies have shown that impaired intestinal barrier function permits penetration of harmful molecules into the underlining colonic lamina propria and initiates and/or perpetuates the intestinal inflammation. 2 Abrogation of oral tolerance to normal enteric flora is thought to be important in T helper type 1 (Th1)-mediated experimental colitis models. 3 In fact, some commensal bacteria have been postulated to be associated with the development of IBD. 4, 5 However, the factors that are actually involved in the host/microbial interaction have remained to be identified.
DNA-microarray analysis has been used widely as a powerful approach to identify novel and unexpected molecules associated with inflammation. 6 By utilizing this approach, we have found that chitinase 3-like 1 (CHI3L1 also known as YKL40 or HC-gp39), which interacts with a carbohydrate polymer (chitin), is involved in the exacerbation of intestinal inflammation by enhancing the bacterial/CEC interaction. 6 In the last few years, there have been a growing number of publications concerning chitinases and chitinaselike molecules including CHI3L1. Amino acid sequence analysis reveals that CHI3L1 belongs to the glycohydrolase family 18, 7 but the complete characterization of the in vivo biological functions of CHI3L1 remains to be established. We herein review potentially important roles of mammalian chitinases, including CHI3L1, in immune responses under inflammatory conditions, and discuss the potential novel therapeutic strategy of anti-chitinases antibodies.
Mammalian chitinases
More than one billion tons per year of chitin, a polymer of β-1, 4-N-acetyl-glucosamine (GlcNAc), are produced by almost all living organisms including insects; fungi; crustaceans; and other marine organisms, but not by mammals. 8 Despite its strong resistance against chemicals, insolubility, and abundant production, chitin does not accumulate in most ecosystems, suggesting that chitin is degraded by efficient processes in nature. In fact, chitin is degraded by chitinases (EC 3.2.1.14) that belong to members of the glycohydrolase family 18. This family that is characterized by an eight-fold α/ β barrel structure includes bacterial as well as plant chitinases. 9 In addition to being important for energy exchange, chitin degradation is essential in a variety of biological processes. For example, chitin-containing organisms produce chitinases to remodel their structures. 10 Plants are known to produce chitinases to protect themselves from damage by chitin-containing microorganisms such as fungi. 8 Chitinases have been generally considered to lack in mammalian bodies due to the absence of chitin. However, recent studies have identified chitinases and chitinaselike proteins (CLPs) belonging to the glycohydrolase family 18 in mice and human. The members of mammalian chitinases and CLPs include chitinase 3-like-1 (CHI3L1), 1 1 chitotriosidase, 1 2 YKL-39, 1 3 Ym1, 1 4 acidic mammalian chitinase (AMCase), 1 5 oviduct-specific glycoprotein 1 6 and stabilin-1-interacting chitinase-like protein. 17 Chitotriosidase and AMCase possess chitinase enzymatic activity, whereas other mammalian chitinases, including CLPs, do not possess this activity. 1 8 Mammalian chitinases with enzymatic activity have a chitinbinding domain that contains six cysteine residues responsible for their binding to chitin. 19 In contrast, CLPs do not contain such typical chitin-binding domains, but still can bind to chitin with high affinity. oviduct-specific glycoprotein 16 and stabilin-1-interacting (SI)-CLP. 17 These mammalian chitinases possess a conserved sequence motif (DXXDXDXE) on strand β4, and catalytic activity in these chitinases is mediated by the glutamic acid (E), which protonates the glycosidic bond with chitin. 26 AMCase and chitotriosidase have catalytic activity but CHI3L1, YKL-39, Ym1, oviductin, SI-CLP do not have this activity. 17 Due to the substitution of an essential glutamic acid residue to leucine, 11 CHI3L1 has no chitinase activity, 1 1 but still can bind to chitin and chito-oligosaccharides with high affinity through a preserved hydrophobic substrate binding cleft. 24, 27 CHI3L1 also interacts with glycosaminoglycans such as heparin and hyaluronan. 23, 28 The putative heparin-binding site is GRRDKQH (residues 143-149). 2 7 Furthermore, Bigg et al. have recently reported an ability of CHI3L1 to bind to collagen type 1, 2 and 3.
29 CHI3L1 has therefore been defined as a CLP or chitinase-like lectin (Chi-lectin)
What is the physiological function of CHI3L1?
The physiological and biological functions of CHI3L1 are still unclear. However, the studies regarding arthritis, cancer, and liver fibrosis 1 1, 2 5, 3 0, 3 1 suggest that CHI3L1 plays an important role in the processes of inflammation and tissue remodeling. Although CHI3L1 is not synthesized under state of health, an induction of this protein expression is observed in the patients with rheumatoid arthritis and IBD/colorectal carcinoma. 3 2 This observation suggests that CHI3L1 expression is induced under several inflammatory and malignant conditions. Recklies et al. 33 reported that CHI3L1 increases growth rates of fibroblasts by synergistically working with IGF-1 (insulin-like growth factor-1) in growth stimulation. CHI3L1 possesses abilities to activate mitogen-activated protein (MAP) kinase and phosphoinositide kinase-3 (PI-3K) signaling cascades in fibroblasts to control mitogenesis. 33 Recently, Ling et al. 34 showed that stimulation of human articular chondrocytes or skin fibroblasts with CHI3L1 suppresses the cytokine-induced secretion of metalloproteinase (MMP)-1, MMP-3, MMP-13 and the chemokine IL-8. This finding suggests that CHI3L1 elicits an anti-catabolic effect preserving extracellular matrix (ECM) during tissue remodeling/destruction. 3 4 Our group demonstrated that CHI3L1 stimulation significantly activates NF-kB transcription in human colon cell lines and enhances the production of TNFα, IL-8, RANTES and eotaxin. 3 5 These findings suggest that CHI3L1 may play a crucial role in the pathogenesis of colitis by enhancing the production of proinflammatory cytokines and chemokines by CECs.
CHI3L1 in IBD
We have demonstrated that CHI3L1 is expressed by CECs and lamina propria cells (mainly macrophages) under several intestinal inflammatory conditions observed in TCRα-and IL-10 knockout (KO) mice as well as DSS-induced colitis. 6 In contrast, the expression of CHI3L1 is undetectable in colons without colitis. Enhanced CHI3L1 mRNA expression is also detectable in patients with active but not quiescent IBD (both UC and CD) or normal individuals. 6 Interestingly, it has previously been reported that there is a positive correlation between serum CHI3L1 and C-reactive protein (CRP, a marker for the severity of inflammation) levels in UC patients. 36 Therefore, it could be predicted that CHI3L1 is upregulated in inflammatory conditions, including both acute and chronic colitis. In fact, endogenous CHI3L1 mRNA level was found to be significantly upregulated after the stimulation with pro-inflammatory cytokines (TNFα, IL-1βand IL-6) in CEC lines.
To investigate the potential role of CHI3L1 in host/ microbial interaction, CHI3L1-overexpressing CEC lines were infected with Salmonella typhimurium and adherent invasive E. coli (AIEC). Surprisingly, significantly enhanced adhesion and invasion rates were found in these two bacteria on CHI3L1-overexpressing cells. CHI3L1-mediated bacterial adhesion and invasion were significantly inhibited by pretreatment with anti-CHI3L1 specific antibody. An AIEC LF82 strain has been characterized as potentially pathogenic bacteria in the colons of CD patients by the strong and efficient ability in adhesion to and invasion into intestinal epithelial cells and macrophages. 37 In contrast, non-pathogenic E. coli (e.g., DH5α strain) does not adhere to or invade into CHI3L1 overexpressing CECs. 9 Therefore, it is possible that CHI3L1 on CECs may specifically enhance the adhesion and invasion of pathogenic (S. typhimurium) and potentially pathogenic (AIEC) but not non-pathogenic (DH5 α) bacteria. These in vitro data are further confirmed by in vivo experiments; anti-CHI3L1 Ab treatment significantly reduces the translocation of orally inoculated S. typhimurium to host peripheral tissues (e.g., spleen, mesenteric lymph nodes, and liver) compared to control rabbit IgG-treated mice. 6 In addition, neutralization of CHI3L1 by anti-CHI3L1 Ab significantly suppressed DSS-induced acute colitis. 6 Therefore, these results strongly suggest that CHI3L1 on CECs possesses the ability to enhance the adhesion and invasion of intracellular bacteria and acts as a pathogenic mediator of intestinal inflammation.
Possible role of chitin-binding proteins (CBPs) in bacteria/CECs interaction
Plant chitinases have been shown to possess anti-fungal and anti-viral effects through the binding to chitin. 38 The chitin-binding domain of plant chitinases efficiently interacts with as well as digests chitin-containing organisms. 39 Interestingly, the chitin-binding domain is structurally preserved within mammalian CLPs including CHI3L1. Of note, Vaaje-Kolstad et al. recently demonstrated that a gram-negative bacterium, Serratia marcescens, expresses a chitin-binding protein, CBP21, which enhances chitin accessibility to bacterial chitinases. 4 0 CBP21 is 18 kDa protein with a structure consisting of a three-stranded and a four-stranded β-sheet that forms a β-sandwich. 40 Through the sequence similarity, CBP21 is classified as a part of the CBM (carbohydrate-binding module) family 33 1 3 and identified to possess a chitin binding domain. Within the 80 CBP sequences present in the Pfam database, 19 other bacterial CBPs cluster within CBP21. A multiple alignment revealed 40 highly conserved residues (>90% conserved) and a cluster of conserved, mainly hydrophilic, residues at the surface of CBP21. 40 Importantly, the majority of chitinase-producing pathogenic microorganisms contain a gene encoding for the homologue of the cbp21 gene, suggesting the presence of a potential binding ability of chitinase-producing pathogenic bacteria to chitin via CBP21 homologue. 41 Therefore, it is possible that CHI3L1 may bind to a complex of chitin/CBP that is formed on bacteria and this binding may subsequently enhance the adhesion and invasion of these bacteria to CECs. Our group is currently investigating this possibility.
Role of other mammalian chitinases in inflammation
including AMCase and Ym-1
T helper (Th) -2-associated inflammation was originally thought serve as a means to combat parasitic infections, whereas allergy, including atopic asthma, arises as a consequence of poorly controlled Th2-type immune responses elicited independently of parasitic infection. 4 2 It has been demonstrated that AMCase and Ym1 are specifically upregulated in response to Th2-mediated inflammation in the lung. 43 As shown in Fig 1,  a Th2-specific, interleukin-(IL)-13-mediated induction of AMCase by airway epithelial cells and macrophages may underlie the development of airway hyperresponsiveness and inflammatory cell infiltration after exposure to an allergen in asthma patients and murine models of asthma. 4 3 Expression of AMCase in the lung epithelial cells induces the production of monocyte chemoattractant protein (MCP-1) and eotaxin-1, and subsequently contributes to the pathogenesis of asthma 4 3 [ Fig 1] . Allosamidine (pan-chitinase inhibitor) significantly ameliorates Th2 inflammation and airway hypersensitivity, in part by inhibiting IL-13 pathway activation and chemokine production. 43 Therefore, chitinases have been proposed as a potential therapeutic target in Th2-mediated inflammation. 4 3 Moreover, Homer et al. 4 4 showed in two different models of Th2 inflammation that Ym1 and AMCase are exclusively expressed in proximal and distal airway epithelium, respectively. Ym1 is a protein found to be synthesized by and secreted from murine activated peritoneal macrophages through oral infection with nematodes (e.g. Trichinella spiralis). 1 8 Interesting- ly, Ramanathan et al. 45 reported an increased expression of AMCase in chronic rhinosinusitis with nasal polyps. Failure of medical and surgical therapy in chronic rhinosinusitis with nasal polyp is associated with significantly increased expression of AMCase, which may induce repeated bacterial infections. These findings suggest that AMCase may potentially enhance the bacterial interaction, similar to CHI3L1. Therefore, AMCase will be a potentially therapeutic target in chronic rhinosinusitis.
Therapeutic strategy of anti-chitinases in allergic as well as inflammatory diseases
In combination with studies highlighting the expression of CPLs and AMCase, these studies emphasize the potential importance of chitinases as critical mediators of Th2 responses. Neutralization of AMCase activity in vivo by administration of anti-AMCase Ab or a panchitinase inhibitor significantly ameliorates airway inflammation as well as airway hyperresponsiveness. 4 3 This study suggests that AMCase is a potential therapeutic target that can be manipulated to control asthma and other forms of Th2-mediated inflammation.
Our group also showed that neutralization of CHI3L1 by anti-CHI3L1 Ab significantly suppresses DSSinduced acute colitis. 6 To neutralize CHI3L1, we generated anti-CHI3L1 Ab by immunization of rabbits with mouse CHI3L1 peptide 325-339 amino acid residues (n-WVGYDDQESVKS/NKVQ-c) that is located within the chitin-binding motif. The immune serum of CHI3L1 antibody was further purified by affinity purification with the peptide used for the immunization. The specificity of this Ab to CHI3L1 protein has been confirmed by ELI-SA and western blot. Therefore, these studies strongly suggest neutralization of CHI3L1 as a potential novel therapeutic approach for IBD by blocking the adhesion and invasion of intracellular bacteria and by inhibiting the production of pathogenic mediators (including proinflammatory cytokines and chemokines) [Fig 2] . 
Summary
CHI3L1 that is capable of binding to chitin and chitooligosaccharide without a glycohydrolase activity acts as a pathogenic mediator in acute colitis by enhancing the adhesion and invasion of intracellular bacteria to CECs. Other mammalian chitinases, including AMCase also possess the ability to exacerbate local inflammation by facilitating the production of chemical mediators. Therefore, further understanding of the biological roles of mammalian chitinases would provide intervention to develop novel therapeutic approaches for several diseases including asthma, chronic rhinosinusitis, and IBD.
